Side effects of ofloxacin in clinical trials and in postmarketing surveillance
Related Experiment Videos
Abstract:
Data derived from clinical trials of ofloxacin in 15,962 patients show that the incidence rate of adverse drug events was 4.27 per 100 patients. Symptoms were generally mild and related to the gastrointestinal tract, nervous system or hypersensitivity reactions in rank order. On the other hand, spontaneous reports obtained during postmarketing surveillance involving 1.5 million patients showed that the most frequent adverse drug events were related to the nervous system; next in order of frequency were hypersensitivity reactions and gastrointestinal symptoms. A comparison of the data obtained from clinical trials and postmarketing surveillance revealed no change in the favourable overall benefit:risk ratio of ofloxacin. Possible reasons for the different patterns of adverse drug events are discussed.
Insights
Ofloxacin demonstrates a favorable benefit:risk ratio, with generally mild adverse events. Clinical trials and postmarketing surveillance show consistent safety profiles for this important antibiotic.
Area of Science:
- Pharmacovigilance
- Clinical Pharmacology
- Infectious Diseases
Background:
- Ofloxacin is a widely used fluoroquinolone antibiotic.
- Understanding its safety profile across different patient populations and data sources is crucial for clinical practice.
Purpose of the Study:
- To compare the incidence and types of adverse drug events (ADEs) of ofloxacin from clinical trials versus postmarketing surveillance.
- To assess the overall benefit:risk ratio of ofloxacin based on comprehensive safety data.
Main Methods:
- Analysis of ADE data from 15,962 patients in ofloxacin clinical trials.
- Review of spontaneous ADE reports from postmarketing surveillance involving 1.5 million patients.
- Comparative analysis of ADE patterns between clinical trial data and real-world postmarketing data.
Main Results:
- Clinical trials reported an ADE incidence rate of 4.27 per 100 patients, with gastrointestinal, nervous system, and hypersensitivity events being most common.
- Postmarketing surveillance identified nervous system events as most frequent, followed by hypersensitivity and gastrointestinal symptoms.
- Despite differing patterns in specific ADEs, the overall benefit:risk ratio of ofloxacin remained favorable and unchanged.
Conclusions:
- Ofloxacin maintains a favorable benefit:risk profile, supported by both clinical trial and real-world postmarketing data.
- Minor variations in reported ADE frequencies between study types may exist but do not alter the drug's established safety.
- Continued monitoring of ofloxacin safety is essential to ensure sustained therapeutic benefit.